1-12 of 12
chemotherapy, neoadjuvant
Close
Sort by
Journal Articles

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Damodaran Narayanan, Olga Pozdnyakova, Robert P. Hasserjian, Sanjay S. Patel, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2021) 5 (11): 2539–2549.
https://doi.org/10.1182/bloodadvances.2021004250
Published: 2021
Includes: Supplemental data
Journal Articles

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

Clinical Trials & Observations
Cheng-Hong Tsai, Jih-Luh Tang, Feng-Ming Tien, Yuan-Yeh Kuo, Dung-Chi Wu, Chien-Chin Lin, Mei-Hsuan Tseng, Yen-Ling Peng, Mei-Fang Hou, Yi-Kuang Chuang, Ming-Chih Liu, Chia-Wen Liu, Ming Yao, Liang-In Lin, Wen-Chien Chou, Chien-Yu Chen, Hsin-An Hou, Hwei-Fang Tien
Journal: Blood Advances
Blood Adv (2021) 5 (10): 2456–2466.
https://doi.org/10.1182/bloodadvances.2020003738
Published: 2021
Includes: Supplemental data
Journal Articles

Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States

Amer M. Zeidan, Nikolai A. Podoltsev, Xiaoyi Wang, Chi Zhang, Jan Philipp Bewersdorf, Rory M. Shallis, Scott F. Huntington, Natalia Neparidze, Smith Giri, Steven D. Gore, Amy J. Davidoff, Xiaomei Ma, Rong Wang
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1615–1623.
https://doi.org/10.1182/bloodadvances.2020001728
Published: 2020
Journal Articles

Single-cell mutational profiling enhances the clinical evaluation of AML MRD

Clinical Trials & Observations
Asiri Ediriwickrema, Alexey Aleshin, Johannes G. Reiter, M. Ryan Corces, Thomas Köhnke, Melissa Stafford, Michaela Liedtke, Bruno C. Medeiros, Ravindra Majeti
Journal: Blood Advances
Blood Adv (2020) 4 (5): 943–952.
https://doi.org/10.1182/bloodadvances.2019001181
Published: 2020
Includes: Supplemental data
Journal Articles

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome

Clinical Trials & Observations
Frances Linzee Mabrey, Kelda M. Gardner, Kathleen Shannon Dorcy, Andrea Perdue, Heather A. Smith, Alicyn M. Davis, Cody Hammer, Donelle Rizzuto, Sunny Jones, Kim Quach, Bart L. Scott, Paul C. Hendrie, Mary-Elizabeth M. Percival, Roland B. Walter, Frederick R. Appelbaum, Elihu H. Estey, Pamela S. Becker
Journal: Blood Advances
Blood Adv (2020) 4 (4): 611–616.
https://doi.org/10.1182/bloodadvances.2019000707
Published: 2020
Includes: Supplemental data
Journal Articles

Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia

Clinical Trials & Observations
Richard C. Harvey, Sarah K. Tasian
Journal: Blood Advances
Blood Adv (2020) 4 (1): 218–228.
https://doi.org/10.1182/bloodadvances.2019000163
Published: 2020
Journal Articles

Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Manuela Zanni, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, Francesca Ricci, Carmelo Carlo-Stella
Journal: Blood Advances
Blood Adv (2020) 4 (1): 136–140.
https://doi.org/10.1182/bloodadvances.2019000984
Published: 2020
Includes: Supplemental data
Journal Articles

Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML

Tracy Murphy, Jinfeng Zou, Georgina S. Daher-Reyes, Andrea Arruda, Vikas Gupta, Caroline J. McNamara, Mark D. Minden, Aaron D. Schimmer, Hassan Sibai, Karen W. L. Yee, Mariam Korulla, Tracy Stockley, Suzanne Kamel-Reid, Dawn Maze, Anne Tierens, Scott V. Bratman, Andre C. Schuh, Steven M. Chan
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2307–2311.
https://doi.org/10.1182/bloodadvances.2019000306
Published: 2019
Includes: Supplemental data
Journal Articles

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Clinical Trials & Observations
Jun Yin, Betsy LaPlant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1714–1721.
https://doi.org/10.1182/bloodadvances.2018026112
Published: 2019
Includes: Supplemental data
Journal Articles

NPM1 mutated AML can relapse with wild-type NPM1 : persistent clonal hematopoiesis can drive relapse

Clinical Trials & Observations
Alexander Höllein, Manja Meggendorfer, Frank Dicker, Sabine Jeromin, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3118–3125.
https://doi.org/10.1182/bloodadvances.2018023432
Published: 2018
Journal Articles

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Clinical Trials & Observations
Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2063–2071.
https://doi.org/10.1182/bloodadvances.2018015529
Published: 2018
Includes: Supplemental data
Journal Articles

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy

Sara Mastaglio, Eric Wong, Travis Perera, Jane Ripley, Piers Blombery, Mark J. Smyth, Rachel Koldej, David Ritchie
Journal: Blood Advances
Blood Adv (2018) 2 (4): 335–346.
https://doi.org/10.1182/bloodadvances.2017015230
Published: 2018
Includes: Supplemental data